发明申请
US20060178387A1 Combined treatment with capecitabine and an epidermal growth factor receptor kinase inhibitor
审中-公开
联合治疗卡培他滨和表皮生长因子受体激酶抑制剂
- 专利标题： Combined treatment with capecitabine and an epidermal growth factor receptor kinase inhibitor
- 专利标题（中）： 联合治疗卡培他滨和表皮生长因子受体激酶抑制剂
-
申请号： US11345894申请日： 2006-02-02
-
公开(公告)号： US20060178387A1公开(公告)日： 2006-08-10
- 发明人: Kaori Fujimoto-Ouchi , Fumiko Sekiguchi , Yutaka Tanaka , Mieko Yanagisawa
- 申请人： Kaori Fujimoto-Ouchi , Fumiko Sekiguchi , Yutaka Tanaka , Mieko Yanagisawa
- 主分类号： A61K31/513
- IPC分类号： A61K31/513
摘要：
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and capecitabine combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and capecitabine combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as TARCEVA®).
信息查询
IPC分类:
